diisopropyl imidocarbonate | 125152-26-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: diisopropyl imidocarbonate
• 英文别名: Di(propan-2-yloxy)methanimine
• CAS: 125152-26-3
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: HDKOIGIKOFNLEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  42.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基-2-硝基丙腈 、 sodium isopropylate 以 异丙醇 为溶剂， 反应 1.0h， 以75.4%的产率得到diisopropyl imidocarbonate
  参考文献：
  名称：

  Matacz, Zygmunt; Piotrowska, Hanna; Poplawska, Magdalena, Bulletin of the Polish Academy of Sciences: Chemistry, 1988, vol. 36, # 3-4, p. 139 - 146

  摘要：

  DOI：

文献信息

• Synthesis of esters of iminocarbonic acid
  作者：V. A. Lopyrev、V. N. Kurochkin、I. A. Titova、M. G. Voronkov

  DOI：10.1007/bf00962139

  日期：1989.10
• LOPYREV, V. A.;KUROCHKIN, V. N.;TITOVA, I. A.;VORONKOV, M. G., IZV. AN CCCP. CEP. XIM.,(1989) N0, S. 2363-2365
  作者：LOPYREV, V. A.、KUROCHKIN, V. N.、TITOVA, I. A.、VORONKOV, M. G.

  DOI：——

  日期：——
• PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL
  申请人：Lonza Ltd

  公开号：EP1592672A2

  公开（公告）日：2005-11-09
• Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol
  申请人：Schmidt Beat

  公开号：US20060100430A1

  公开（公告）日：2006-05-11

  A process for preparing a 2-alkoxy-6-(trifluoromethyl)pyrimidine-4-ol of the formula I: wherein R is C 1 -C 8 alkyl. First a cyanogen halide, that is, cyanogen chloride ClCN or cyanogen bromide BrCN, is reacted with a C 1 -C 8 alcohol ROH and/or a C 1 -C 8 alcoholate in the presence of a base to give the corresponding symmetric imidocarbonic acid dialkylester of the formula II: In a second step, the imidocarbonic acid diakylester is reacted with trifluoromethyl acetoacetic acid ethyl ester in the presence of ammonia to yield the compound of formula I.
• DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS
  申请人：XU Qiaobing

  公开号：US20160009643A1

  公开（公告）日：2016-01-14

  A compound of formula the following formula: (I). In this formula, moieties A, B, X, R 1 , R 2 , and R 3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.